Serum autoantibodies for the diagnosis and management of autoimmune liver diseases

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 6, 2012, Pages 717-729

  Achenza, Maria Is ^a   Meda, Francesca ^a   Brunetta, Enrico ^a   Selmi, Carlo ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

autoimmune hepatitis; diagnosis; pathogenesis; primary biliary cirrhosis; primary sclerosing cholangitis

Indexed keywords

ALPHA ACTIN ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BILIARY EPITHELIAL CELL ANTIBODY; LIVER CYTOSOL 1 ANTIBODY; LIVER KIDNEY MICROSOMIAL ANTIBODY; LIVER PANCREAS ANTIBODY; MITOCHONDRION ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; SMOOTH MUSCLE ANTIBODY; SOLUBLE LIVER ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; AUTOIMMUNE HEPATITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPRECIPITATION; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN EXPRESSION; REVIEW; WESTERN BLOTTING;

ACTINS; ADRENAL CORTEX HORMONES; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CHOLANGITIS, SCLEROSING; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY;

EID: 84871027098     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.58     Document Type: Review

References (129)

1. Agmon-Levin N, Shapira Y, Selmi C et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J. Autoimmun. 34(1), 55-58 (2010).
2. Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun. Rev. 11(6-7), A386-A392 (2012).
3. Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J. Gastroenterol. Hepatol. 18(10), 1118-1128 (2003). (Pubitemid 37410040)
4. Nakanishi Y, Tsuneyama K, Fujimoto M et al. Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J. Autoimmun. 30(1-2), 42-50 (2008).
5. Sharma R, Fu SM, Ju ST. IL-2: a two-faced master regulator of autoimmunity. J. Autoimmun. 36(2), 91-97 (2011).
6. Ullal AJ, Reich CF 3rd, Clowse M et al. Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. J. Autoimmun. 36(3-4), 173-180 (2011).
7. Ospelt C, Reedquist KA, Gay S, Tak PP. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? Autoimmun. Rev. 10(9), 519-524 (2011).
8. Conrad K, Roggenbuck D, Reinhold D, Sack U. Autoantibody diagnostics in clinical practice. Autoimmun. Rev. 11(3), 207-211 (2012).
9. Bonaguri C, Melegari A, Ballabio A et al. Italian multicentre study for application of a diagnostic algorithm in autoantibody testing for autoimmune rheumatic disease: conclusive results. Autoimmun. Rev. 11(1), 1-5 (2011).
10. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J. Gastroenterol. 14(21), 3374-3387 (2008).
11. Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J. Autoimmune Dis. 1(1), 2 (2004).
12. Krawitt EL. Autoimmune hepatitis. N. Engl. J. Med. 354(1), 54-66 (2006). (Pubitemid 43048951)
13. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand. J. Gastroenterol. 33(1), 99-103 (1998). (Pubitemid 28114077)
14. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J. Hepatol. 40(1), 3-7 (2004). (Pubitemid 38064706)
15. Mieli-Vergani G, Heller S, Jara P et al. Autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 49(2), 158-164 (2009).
16. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31(5), 929-938 (1999). (Pubitemid 29514229)
17. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 18(4), 998-1005 (1993).
18. Hennes EM, Zeniya M, Czaja AJ et al.; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48(1), 169-176 (2008). (Pubitemid 351975541)
19. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am. J. Gastroenterol. 97(2), 413-419 (2002). (Pubitemid 34160769)
20. Leung PS, Coppel RL, Ansari A, Munoz S, Gershwin ME. Antimitochondrial antibodies in primary biliary cirrhosis. Semin. Liver Dis. 17(1), 61-69 (1997). (Pubitemid 27157372)
21. Cowling DC, Mackay IR, Taft LI. Lupoid hepatitis. Lancet 271(6957), 1323-1326 (1956).
22. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun. Rev. 9(5), A259-A266 (2010).
23. Whittingham S, Irwin J, Mackay IR, Smalley M. Smooth muscle autoantibody in 'autoimmune' hepatitis. Gastroenterology 51(4), 499-505 (1966).
24. Johnson GD, Holborow EJ, Glynn LE. Antibody to smooth muscle in patients with liver disease. Lancet 2(7418), 878-879 (1965).
25. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 24(5), 1068-1073 (1996). (Pubitemid 26365905)
26. Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 35(8), 515-519 (2002). (Pubitemid 36321892)
27. Guéguen P, Dalekos G, Nousbaum JB et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J. Clin. Immunol. 26(6), 495-505 (2006).
28. Renaudineau Y, Dalekos GN, Guéguen P, Zachou K, Youinou P. Anti-α-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin. Rev. Allergy Immunol. 34(3), 321-325 (2008).
29. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin. Exp. Immunol. 15(3), 331-344 (1973).
30. Rizzetto M, Bianchi FB, Doniach D. Characterization of the microsomal antigen related to a subclass of active chronic hepatitis. Immunology 26(3), 589-601 (1974).
31. Crivelli O, Lavarini C, Chiaberge E et al. Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin. Exp. Immunol. 54(1), 232-238 (1983). (Pubitemid 13052130)
32. Fabien N, Desbos A, Bienvenu J, Magdalou J. Autoantibodies directed against the UDP-glucuronosyltransferases in human autoimmune hepatitis. Autoimmun. Rev. 3(1), 1-9 (2004). (Pubitemid 38197964)
33. Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC. Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 4(2), 315-323 (1984). (Pubitemid 14131442)
34. Iijima Y, Kato T, Miyakawa H et al. Effect of interferon therapy on Japanese chronic hepatitis C virus patients with anti-liver/ kidney microsome autoantibody type 1. J. Gastroenterol. Hepatol. 16(7), 782-788 (2001). (Pubitemid 34188816)
35. Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J. Exp. Med. 168(2), 801-806 (1988).
36. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc. Natl Acad. Sci. USA 85(21), 8256-8260 (1988).
37. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J. Clin. Invest. 83(3), 1066-1072 (1989). (Pubitemid 19080643)
38. Vergani D. LKM antibody: getting in some target practice. Gut 46(4), 449-450 (2000). (Pubitemid 30305803)
39. Manns MP, Johnson EF. Identification of human cytochrome P450s as autoantigens. Meth. Enzymol. 206, 210-220 (1991).
40. Kerkar N, Choudhuri K, Ma Y et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J. Immunol. 170(3), 1481-1489 (2003). (Pubitemid 36139518)
41. Muratori L, Parola M, Ripalti A et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 46(4), 553-561 (2000). (Pubitemid 30305822)
42. Vitozzi S, Djilali-Saiah I, Lapierre P, Alvarez F. Anti-soluble liver antigen/ liver-pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity 35(8), 485-492 (2002). (Pubitemid 36321888)
43. Costa M, Rodríguez-Sánchez JL, Czaja AJ, Gelpí C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin. Exp. Immunol. 121(2), 364-374 (2000). (Pubitemid 30659778)
44. Lindgren S, Nilsson S, Nässberger L, Verbaan H, Wieslander J. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK). J. Gastroenterol. Hepatol. 15(4), 437-442 (2000). (Pubitemid 30262213)
45. Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 8(6), 1662-1666 (1988). (Pubitemid 19021905)
46. Muratori L, Cataleta M, Muratori P et al. Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. J. Immunol. Methods 187(2), 259-264 (1995).
47. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 42(5), 721-726 (1998). (Pubitemid 28261064)
48. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 377(9777), 1600-1609 (2011).
49. Metcalf JV, Bhopal RS, Gray J, Howel D, James OF. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int. J. Epidemiol. 26(4), 830-836 (1997). (Pubitemid 27367860)
50. Invernizzi P, Miozzo M, Battezzati PM et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 363(9408), 533-535 (2004). (Pubitemid 38229455)
51. Hirschfield GM, Liu X, Xu C et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N. Engl. J. Med. 360(24), 2544-2555 (2009).
52. Mells GF, Floyd JA, Morley KI et al.; UK PBC Consortium; Wellcome Trust Case Control Consortium 3. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat. Genet. 43(4), 329-332 (2011).
53. Rigopoulou EI. Molecular diagnostics of primary biliary cirrhosis. Expert Opin. Med. Diagn. 2, 621-634 (2008). (Pubitemid 351997852)
54. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J. Immunol. 138(10), 3525-3531 (1987). (Pubitemid 17071942)
55. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet 1(7390), 827-831 (1965).
56. Homberg JC, Abuaf N, Bernard O et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 7(6), 1333-1339 (1987). (Pubitemid 18014211)
57. Nakanuma Y, Harada K, Kaji K et al. Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies. Liver 17(6), 281-287 (1997). (Pubitemid 28014676)
58. Muratori P, Muratori L, Gershwin ME et al. 'True' antimitochondrial antibodynegative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin. Exp. Immunol. 135(1), 154-158 (2004). (Pubitemid 38067940)
59. Moteki S, Leung PS, Coppel RL et al. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Hepatology 24(1), 97-103 (1996). (Pubitemid 26249419)
60. Gabeta S, Norman GL, Liaskos C et al. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J. Clin. Immunol. 27(4), 378-387 (2007). (Pubitemid 46906660)
61. Oertelt S, Rieger R, Selmi C et al. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 45(3), 659-665 (2007). (Pubitemid 46450617)
62. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N. Engl. J. Med. 353(12), 1261-1273 (2005). (Pubitemid 41345948)
63. Cunha LM, Bittencourt PL, Abrantes-Lemos CP et al. Prevalence of non-organ-specific autoantibodies in a rural community from northeastern Brazil: a population-based study. Hum. Immunol. 73(1), 70-74 (2012).
64. Turchany JM, Uibo R, Kivik T et al. A study of antimitochondrial antibodies in a random population in Estonia. Am. J. Gastroenterol. 92(1), 124-126 (1997). (Pubitemid 27027042)
65. Shibata M, Onozuka Y, Morizane T et al. Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture. J. Gastroenterol. 39(3), 255-259 (2004). (Pubitemid 38519431)
66. Grimbert S, Johanet C, Bendjaballah F, Homberg JC, Poupon R, Beaugrand M. Antimitochondrial antibodies in patients with chronic hepatitis C. Liver 16(3), 161-165 (1996). (Pubitemid 26280482)
67. Ramos-Casals M, Pares A, Jara LJ et al.; HISPAMEC Study Group. Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. J. Viral Hepat. 12(6), 648-654 (2005). (Pubitemid 41532497)
68. Floreani A, Baragiotta A, Leone MG, Baldo V, Naccarato R. Primary biliary cirrhosis and hepatitis C virus infection. Am. J. Gastroenterol. 98(12), 2757-2762 (2003). (Pubitemid 38020120)
69. Mitchison HC, Bassendine MF, Hendrick A et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 6(6), 1279-1284 (1986). (Pubitemid 17210555)
70. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 348(9039), 1399-1402 (1996). (Pubitemid 26395233)
71. Liu H, Norman GL, Shums Z et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J. Autoimmun. 35(4), 436-442 (2010).
72. Christensen E, Crowe J, Doniach D et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78(2), 236-246 (1980). (Pubitemid 10128493)
73. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N. Engl. J. Med. 308(1), 1-7 (1983). (Pubitemid 13211264)
74. Heseltine L, Turner IB, Fussey SP et al. Primary biliary cirrhosis. Quantitation of autoantibodies to purified mitochondrial enzymes and correlation with disease progression. Gastroenterology 99(6), 1786-1792 (1990).
75. Bogdanos DP, Liaskos C, Pares A et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 45(6), 1583; author reply 1583-1584 (2007). (Pubitemid 46918344)
76. Van Norstrand MD, Malinchoc M, Lindor KD et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 25(1), 6-11 (1997). (Pubitemid 27014977)
77. Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am. J. Gastroenterol. 97(4), 999-1002 (2002). (Pubitemid 34408260)
78. Masuda J, Omagari K, Ohba K et al. Correlation between histopathological findings of the liver and IgA class antibodies to 2-oxo-acid dehydrogenase complex in primary biliary cirrhosis. Dig. Dis. Sci. 48(5), 932-938 (2003). (Pubitemid 36470215)
79. Omagari K, Kadokawa Y, Nakamura M et al. IgA class antibodies to 2-oxo-acid dehydrogenase complex are not predictive markers of histopathological progression in primary biliary cirrhosis. Autoimmunity 39(2), 107-112 (2006). (Pubitemid 43675253)
80. Brunner G, Klinge O. A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis). Dtsch. Med. Wochenschr. 112(38), 1454-1458 (1987). (Pubitemid 17127032)
81. Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am. J. Gastroenterol. 90(2), 247-249 (1995).
82. Szostecki C, Guldner HH, Netter HJ, Will H. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J. Immunol. 145(12), 4338-4347 (1990).
83. Szostecki C, Will H, Netter HJ, Guldner HH. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand. J. Immunol. 36(4), 555-564 (1992).
84. Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. Autoantibodies from patients with primary biliary cirrhosis preferentially react with the amino-terminal domain of nuclear pore complex glycoprotein gp210. J. Exp. Med. 182(4), 1159-1162 (1995).
85. Wesierska-Gadek J, Hohenuer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 110(3), 840-847 (1996). (Pubitemid 26071851)
86. Yang Z, Liang Y, Qin B et al. Clinical significance of conventional serum autoantibodies for various liver diseases in a Chinese population. Clin. Biochem. 54(3), 203-206 (2012).
87. Rigopoulou EI, Davies ET, Pares A et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 54(4), 528-532 (2005). (Pubitemid 40395506)
88. Muratori P, Muratori L, Cassani F et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin. Exp. Immunol. 127(1), 172-175 (2002). (Pubitemid 34155473)
89. Luettig B, Boeker KH, Schoessler W et al. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. J. Hepatol. 28(5), 824-828 (1998). (Pubitemid 28223487)
90. Züchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 26(5), 1123-1130 (1997). (Pubitemid 27509292)
91. Invernizzi P, Podda M, Battezzati PM et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J. Hepatol. 34(3), 366-372 (2001). (Pubitemid 32240814)
92. Wesierska-Gadek J, Penner E, Battezzati PM et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43(5), 1135-1144 (2006). (Pubitemid 43724638)
93. Wesierska-Gadek J, Klima A, Ranftler C et al. Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen. J. Cell. Biochem. 104(1), 27-37 (2008).
94. Wesierska-Gadek J, Klima A, Komina O, Ranftler C, Invernizzi P, Penner E. Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies. Ann. NY Acad. Sci. 1109, 519-530 (2007). (Pubitemid 47511395)
95. Milkiewicz P, Buwaneswaran H, Coltescu C, Shums Z, Norman GL, Heathcote EJ. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin. Gastroenterol. Hepatol. 7(12), 1355-1360 (2009).
96. Nakamura M, Kondo H, Mori T et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45(1), 118-127 (2007). (Pubitemid 46144371)
97. Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin. Gastroenterol. Hepatol. 2(12), 1116-1122 (2004). (Pubitemid 40037643)
98. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin. Liver Dis. 26(1), 22-30 (2006). (Pubitemid 43320724)
99. Bambha K, Kim WR, Talwalkar J et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125(5), 1364-1369 (2003). (Pubitemid 37409756)
100. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin. Liver Dis. 11(1), 31-39 (1991).
101. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin. Liver Dis. 26(1), 3-21 (2006). (Pubitemid 43320723)
102. Yamada S, Ishii M, Liang LS, Yamamoto T, Toyota T. Small duct cholangitis induced by N-formyl l-methionine l-leucine l-tyrosine in rats. J. Gastroenterol. 29(5), 631-636 (1994). (Pubitemid 24308414)
103. Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 13(4), 766-772 (1991).
104. Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J. Gastroenterol. 14(21), 3350-3359 (2008).
105. Duerr RH, Targan SR, Landers CJ et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 100(5 Pt 1), 1385-1391 (1991).
106. Claise C, Johanet C, Bouhnik Y, Kapel N, Homberg JC, Poupon R. Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases. Liver 16(1), 28-34 (1996).
107. Klein R, Klöppel G, Garbe W, Fintelmann V, Berg PA. Antimitochondrial antibody profiles determined at early stages of primary biliary cirrhosis differentiate between a benign and a progressive course of the disease. A retrospective analysis of 76 patients over 6-18 years. J. Hepatol. 12(1), 21-27 (1991).
108. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 108(4), 1159-1166 (1995).
109. Mulder AH, Horst G, Haagsma EB, Kleibeuker JH, Kallenberg CG. Antineutrophil cytoplasmic antibodies (ANCA) in autoimmune liver disease. Adv. Exp. Med. Biol. 336, 545-549 (1993).
110. Terjung B, Spengler U, Sauerbruch T, Worman HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 119(2), 310-322 (2000). (Pubitemid 30621981)
111. Roozendaal C, Van Milligen de Wit AW, Haagsma EB et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am. J. Med. 105(5), 393-399 (1998). (Pubitemid 28536224)
112. Bansi DS, Bauducci M, Bergqvist A et al. Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. Eur. J. Gastroenterol. Hepatol. 9(6), 575-580 (1997). (Pubitemid 27267688)
113. Pokorny CS, Norton ID, McCaughan GW, Selby WS. Anti-neutrophil cytoplasmic antibody: a prognostic indicator in primary sclerosing cholangitis. J. Gastroenterol. Hepatol. 9(1), 40-44 (1994). (Pubitemid 24041947)
114. Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 51(1), 120-127 (2002). (Pubitemid 34717756)
115. Karrar A, Broomé U, Södergren T et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 132(4), 1504-1514 (2007). (Pubitemid 46627575)
116. Fathman CG, Soares L, Chan SM, Utz PJ. An array of possibilities for the study of autoimmunity. Nature 435(7042), 605-611 (2005). (Pubitemid 40825500)
117. Iborra M, Bernuzzi F, Invernizzi P, Danese S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun. Rev. 11(5), 305-314 (2012).
118. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J. Autoimmun. 32(3-4), 189-194 (2009).
119. Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. miRNAs and related polymorphisms in rheumatoid arthritis susceptibility. Autoimmun. Rev. 11(9), 636-641 (2012).
120. Zhang W, Ono Y, Miyamura Y, Bowlus CL, Gershwin ME, Maverakis E. T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. J. Autoimmun. 37(2), 71-78 (2011).
121. Bernuzzi F, Fenoglio D, Battaglia F et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J. Autoimmun. 35(3), 176-180 (2010).
122. Fu SM, Deshmukh US, Gaskin F. Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J. Autoimmun. 37(2), 104-112 (2011).
123. Hickman-Brecks CL, Racz JL, Meyer DM, LaBranche TP, Allen PM. Th17 cells can provide B cell help in autoantibody induced arthritis. J. Autoimmun. 36(1), 65-75 (2011).
124. Hintermann E, Holdener M, Bayer M et al. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. J. Autoimmun. 37(3), 242-253 (2011).
125. Naiyanetr P, Butler JD, Meng L et al. Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity. J. Autoimmun. 37(3), 209-216 (2011).
126. Lidar M, Lipschitz N, Agmon-Levin N et al. Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia. Clin. Rev. Allergy Immunol. 42(2), 238-246 (2012).
127. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun. Rev. 11(8), 593-595 (2012).
128. Juran BD, Lazaridis KN. Update on the genetics and genomics of PBC. J. Autoimmun. 35(3), 181-187 (2010).
129. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349(16), 1526-1533 (2003). (Pubitemid 37255038)